1. Introduction {#s0005}
===============

Kidney stones (KS) induce substantial disease burden on men\'s health ([@bb0020]; [@bb0060]). For example, prevalence increased from 6.3% (1988--1994) to 10.6% (2007--2010) in men (4.1% and 7.1% in women, respectively) ([@bb0130]; [@bb0155]), and annual costs associated with KS was estimated to range between \$5 billion ([@bb0035]) and \$10 billion ([@bb0075]) in the U.S.. Although prevalence of KS is historically higher in men than women ([@bb0130]; [@bb0150]; [@bb0155]), we lack further evidence if there is an association between testosterone concentrations and KS ([@bb0135]). Because testosterone concentrations are biologically higher in men than women ([@bb0180]) and are associated with KS ([@bb0085]; [@bb0110]), we aimed to determine the association between low-testosterone (total testosterone ≤3 ng/mL) and KS in men. TT is the combination of bioavailable and sex hormone-binding globulin (SHBG)-bound testosterone.

KS was considered a multifactorial disease due to role thought to play by demographics (eg age, race/ethnicity), and comorbidities (e.g. diabetes, obesity, dyslipidemia) ([@bb0130]; [@bb0150]). Such factors were also associated with change in total testosterone (TT) concentrations in men ([@bb0005]; [@bb0015]; [@bb0120]; [@bb0125]). Obesity was associated with TT concentrations and with KS. For example, 45% of obese men (BMI ≥ 30 kg/m^2^) had low-testosterone ([@bb0120]), and obese men were 55% more likely to report KS ([@bb0130]). Diabetes was associated with TT concentrations ([@bb0015]) and with KS ([@bb0130]). For example, TT concentrations were negatively correlated with diabetes ([@bb0015]), and diabetic men were 59% more likely to have a history of KS ([@bb0130]). Dyslipidemia was associated with low TT concentrations ([@bb0040]; [@bb0170]), and with KS ([@bb0055]; [@bb0080]; [@bb0175]). For example, testosterone was inversely associated with dyslipidemia ([@bb0040]).

Race/ethnicity was associated with both KS and TT concentrations. Prevalence of low testosterone (TT concentrations \<3 ng/mL) was 17.7% in White, 1.7% in Black, and 2.4% in Hispanic men ([@bb0120]), and Hispanic men had TT concentrations significantly higher than those in White men ([@bb0125]). Black men and Hispanic men were 63% and 40% less likely to have a history of KS than White men respectively ([@bb0130]). Age was associated with KS ([@bb0115]; [@bb0130]). KS prevalence was 10.8% (2007--2010) in men, and varied when stratified by age groups (3.4% for 20--29, 6.9% for 30--39, 9.8% for 40--49, 13.1% for 50--59, and 19.1% for 60--69 years) ([@bb0130]). Increasing age was significantly associated with excretion of key urinary compounds related to kidney stones ([@bb0115]), and there was a reverse association between total testosterone concentrations and age ([@bb0030]; [@bb0045]).

Despite all these relationships, there is a paucity of evidence on the association between testosterone and KS and how this relationship varied when stratified by obesity, diabetes, dyslipidemia, race/ethnicity, and age.

2. Methods {#s0010}
==========

2.1. Survey overview, study design, and subjects {#s0015}
------------------------------------------------

This was a cross-sectional study. We analyzed data collected from the National Health and Nutrition Examination Survey (NHANES) 2011--2012. NHANES is a program of studies undertaken by the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC) to assess the health and nutritional status of the US population. NHANES uses a multistage, stratified and clustered probability sampling in which Hispanics, non-Hispanic Blacks, and the elderly were oversampled to ensure adequate sample sizes and to represent the total US civilian, non-institutionalized population. ([@bb0095]) The study population consisted entirely of male respondents, 20 years and older.

2.2. Outcome, exposure, and covariates {#s0020}
--------------------------------------

Data on KS, TT concentrations, demographics, comorbidities, and other covariates were gathered from the 2011--2012 cycle of NHANES. Low-testosterone is defined as TT concentrations \<3 ng/mL. Testosterone is the major male androgen, and free circulating concentrations are controlled by SHBG. Bioavailable testosterone is the concentration of non-SHBG-bound testosterone and is comprised of both free and albumin-bound testosterone. TT is the combination of bioavailable and SHBG-bound testosterone. Testosterone was isolated from 100 μL serum by 2 serial liquid-liquid extraction steps and quantified with \[^13^C\] stable isotope-labeled testosterone as the internal standard. The method had a nonsignificant bias to established reference methods at National Institute for Standards and Technology and the University of Ghent. Imprecision over 2 years was \<4.8%, and the limit of detection was 0.3 ng/dL (0.01 nmol/L).

KS, age, and other covariates are self-reported (e.g. race/ethnicity, marital status, education, alcohol use, prescription drug use, comorbidities, and physical activity. Body Mass Index (BMI) was categorized as normal weight (BMI ≤ 24.9 kg/m^2^), overweight (25.0 ≤ BMI \< 30.0 kg/m^2^), and obese (BMI ≥ 30.0 kg/m^2^). Diabetes was identified as one or more of the following: diabetes diagnosis, fasting plasma glucose levels ≥126 mg/dL, positive response to questions about medication treatment (e.g. "are you now taking insulin?" or "are you now taking diabetic pills to lower your blood sugar?"), glycated hemoglobin level of 6.5% or greater (A1C ≥ 6.5%). Race/ethnicity was collected for White, Non-Hispanic Black, and Hispanic. Prescription drug use, which is associated with KS ([@bb0025]; [@bb0140]), included statins, angiotensin-renin blockers, ACE inhibitors, beta blockers, calcium channel inhibitors, thiazide diuretics, loop diuretics, protease inhibitors, sulfonamides, and aminopenicillins. Other comorbidities included hypertension \[diagnosis or an average of three systolic/diastolic blood pressure readings ≥130/85 mmHg\], heart attack, stroke, congestive heart failure, coronary heart disease, angina pectoris, asthma, bladder cancer, gout, thyroid disease, and daily dietary laboratory data and behavioral data. Age was stratified into four groups for stratification: ≥20--\<40, ≥40--\<60, ≥60--\<80, and ≥80 years.

2.3. Statistical analysis {#s0025}
-------------------------

NHANES analytical reporting guidelines were followed, adhering to the complex survey design. ([@bb0105]) Sampling weights were applied to account for selection probabilities, over-sampling, non-response, and differences between the sample and the total US population. Descriptive statistics for participants\' characteristics were reported with *t*-tests for continuous variables and Chi-square for categorical. Adjusted odds ratios (OR) and 95% confidence intervals (CI) using logistic regression models were estimated in relation to total testosterone concentrations with multiple covariates, and stratified by age groups and comorbidities ([@bb0100]). Outcome was defined as Kidney Stones Exposure was TT concentration \< 3 ng/mL, (Low-testosterone). Statistical significance of tests is set at *p* values \<0.05 (Type I Error). Software utilized for analysis was Stata/IC version 12.1.

3. Results {#s0030}
==========

Descriptive statistics are reported in [Table 1](#t0005){ref-type="table"}. Mean age of men were 48.75 (SD 17.83, 95% CI 48.35--49.14) for those without KS, and 58.58 (SD 15.89, 95% CI 57.53--59.63; *p*-value \<0.001). We found that men 20 years and older with Low-testosterone had 41% lower odds of KS than men without Low-testosterone after multivariable adjustment (OR: 0.59, 95% CI 0.40--0.86, [Table 2](#t0010){ref-type="table"}).Table 1Prevalence estimates (%) for demographic, lifestyle, and clinical factors for 27,904 men, NHANES 2011--2012.Table 1FactorsKidney stones (N, %, or otherwise noted)No kidney stones (N, %, or otherwise noted)*p*-value*N* = 877 (3.14%)*N* = 7749 (%)Age (Mean)58.5848.75\<0.001[⁎](#tf0005){ref-type="table-fn"}Age categories\<0.0001[⁎](#tf0005){ref-type="table-fn"} Age group ≥20 & \<40 years136 (15.51)2778 (35.85) Age group ≥40 & \<60 years266 (30.33)2523 (32.56) Age group ≥60 & \<80 years376 (42.87)1983 (25.59) Age group ≥80 years99 (11.29)465 (6.00)Education categories0.669 Some college or equiv.409 (46.64)3669 (47.40) High school or less468 (53.36)4072 (52.60)Marital status\<0.001[⁎](#tf0005){ref-type="table-fn"} Not married85 (34.98)1224 (49.18) Married158 (30.68)1265 (50.82)Race/ethnicity\<0.0001[⁎](#tf0005){ref-type="table-fn"} White, non-Hispanic515 (58.72)3350 (43.23) Black, non-Hispanic97 (11.06)1740 (22.45) Hispanic215 (24.52)1949 (25.15) Other50 (5.70)710 (9.16)Overall obesity; BMI, (kg/m^2^)\<0.0001[⁎](#tf0005){ref-type="table-fn"} \<25 (ref)161 (18.53)2134 (27.73) 25--29.99336 (38.67)2749 (35.72) ≥30372 (42.81)2812 (36.54)Alcohol use (ALQ101)0.415 Did not have at least 12 alcoholic drinks in one year37 (16.89)317 (14.83) Had at least 12 alcoholic drinks in one year182 (83.11)1821 (85.17)Physical activity0.138 No physical activity502(57.24)4225 (54.53) Moderate activity175 (19.95)1520 (19.62) Vigorous activity200 (22.81)2003 (25.85)Diabetes\<0.0001[⁎](#tf0005){ref-type="table-fn"} No401 (74.81)4485 (86.40) Yes135 (25.19)706 (13.60)Heart attack\<0.0001[⁎](#tf0005){ref-type="table-fn"} No219 (91.80)2388 (96.02) Yes24 (9.88)99 (3.98)Stroke0.001[⁎](#tf0005){ref-type="table-fn"} No224 (91.80)2398 (96.34) Yes20 (8.20)91 (3.66)Congestive heart failure\<0.0001[⁎](#tf0005){ref-type="table-fn"} No221 (91.32)2416 (97.22) Yes21 (8.68)69 (2.78)Coronary heart disease\<0.0001[⁎](#tf0005){ref-type="table-fn"} No215 (89.21)2381 (95.89) Yes26 (10.79)102 (4.11)Angina pectoris\<0.0001[⁎](#tf0005){ref-type="table-fn"} No226 (93.00)2436 (98.15) Yes17 (7.00)46 (1.85)Hypertension\<0.0001[⁎](#tf0005){ref-type="table-fn"} No259 (29.53)3396 (43.83) Yes618 (70.47)4353 (56.17)Asthma0.670 No211 (86.48)2176 (87.42) Yes33 (13.52)313 (12.58)Bladder cancer0.038[⁎](#tf0005){ref-type="table-fn"} No874 (99.66)7742 (99.91) Yes3 (0.34)7 (0.09)Gout\<0.0001[⁎](#tf0005){ref-type="table-fn"} No772 (88.23)7280 (94.03) Yes103 (11.77)462 (5.97)Thyroid disease0.137 No228 (93.83)2385 (95.86) Yes15 (6.17)103 (4.14)Statin use\<0.0001[⁎](#tf0005){ref-type="table-fn"} No592 (67.50)6321 (81.57) Yes285 (32.50)1428 (18.43)Angiotensin-renin blocker use0.680 No242 (99.18)2475 (99.40) Yes2 (0.41)15 (0.60)ACE Inhibitor use0.184 No232 (95.08)2408 (96.71) Yes12 (4.92)82 (3.29)Beta blocker use0.015^⁎⁎^ No234 (95.90)2445 (98.19) Yes10 (4.10)45 (1.81)Ca Channel use0.206 No242 (99.18)2441 (98.03) Yes2 (0.82)49 (1. 79)Thiazide use0.062 No217 (88.93)2299 (92.33) Yes27 (11.07)191 (7.67)Loop diuretic use0.346 No242 (99.18)2480 (99.60) Yes2 (0.82)10 (0.40)Protease Inhibitor use0.036^⁎⁎^ No242 (99.18)2486 (99.84) Yes2 (0.82)4 (0.16)Sulfonamide use0.548 No242 (99.18)2477 (99.48) Yes2 (0.82)13 (0.52)Amino-penicillin use0.436 No241 (98.77)2471 (99.24) Yes3 (1.23)19 (0.76)Total plain water drank yesterday (g) (mean)1847.162029.950.0403Dietary calcium (mg) (mean)925.401030.870.0196[⁎](#tf0005){ref-type="table-fn"}Dietary sodium (mg) (mean)1971.584102.480.006[⁎](#tf0005){ref-type="table-fn"}Dietary protein (g) (mean)85.1296.040.0006[⁎](#tf0005){ref-type="table-fn"}Dietary fat (g) (mean)26.3528.830.0454[⁎](#tf0005){ref-type="table-fn"}Dietary vitamin D (mcg) (mean)5.095.160.8866Dietary caffeine (mg) (mean)156.31158.510.8825Serum vitamin B12 (pg/ml) (mean)552.10593.980.1107Serum HDL-D cholesterol (mg/dL) (mean)45.4648.210.0029[⁎](#tf0005){ref-type="table-fn"}Low salt/low sodium diet0.142 No870 (99.20)7715 (99.56) Yes7 (0.80)34 (0.44)Doctor\'s orders to lose weight\<0.0001[⁎](#tf0005){ref-type="table-fn"} No156 (99.20)1983 (79.64) Yes88 (0.80)507 (20.36)Diet to reduce fat0.211 No112 (45.90)1247 (50.10) Yes132 (54.10)1242 (49.90)Diet to reduce salt0.052 No109 (44.67)1274 (51.19) Yes135 (55.33)1215 (48.81)Increasing exercise0.539 No112 (45.90)1092 (43.86) Yes132 (54.10)1398 (56.14)[^1][^2][^3]Table 2Association between low-testosterone and KS in men (≥20 years), NHANES 2011--2012.Table 2VariableKSOdds Ratio (OR)95% CI*p*-valueTestosterone≥3 ng/mL1.00N/AN/A\<3 ng/mL[⁎](#tf0010){ref-type="table-fn"}0.590.40--0.860.010[⁎](#tf0010){ref-type="table-fn"}Testosterone (ng/mL)1.010.93--1.100.718[^4][^5][^6]

When stratified by obesity, men with BMI ≥ 30 kg/m^2^ and low-testosterone had 59% lower odds of KS versus men without low-testosterone (OR: 0.41, 95% CI: 0.21--0.786), but this association was not statistically significant in BMI levels \<30 kg/m^2^ ([Table 3](#t0015){ref-type="table"}). When stratified by diabetes, there was no association in men with diabetes and low-testosterone, but men without diabetes and with low-testosterone had 39% lower odds of KS (OR: 0.61, 95% CI: 0.42--0.90 ([Table 4](#t0020){ref-type="table"}). When stratified by high density lipid (HDL) levels, men with HDL \> 40 mg/dL and low-testosterone had 40% lower odds of have KS (OR: 0.60, 95% CI: 0.40--0.90), but this association was not significant in men with low-testosterone and with HDL ≤ 40 mg/dL ([Table 5](#t0025){ref-type="table"}). None of the associations was significant in other lipid levels; i.e. low density lipid (LDL) (cut-off = 120 mg/dL), total glycerides (TG) (cut-off = 150 mg/dL), total cholesterol (cut-off = 200 mg/dL or 240 mg/dL) ([Table 5](#t0025){ref-type="table"}).Table 3Stratification by overall obesity in the association between low-testosterone and KS in men (≥20 years), NHANES 2011--2012.Table 3Overall obesity; BMI, kg/m^2^≥3025--29.99\<25TestosteroneOR, 95% CI, *p*-valueOR, 95% CI, *p*-valueOR, 95% CI, *p*-value≥3 ng/mL (ref)1.00, N/A, N/A1.00, N/A, N/A1.00, N/A, N/A\<3 ng/mL0.41, 0.21--0.78, 0.009[⁎](#tf0015){ref-type="table-fn"}0.82, 0.36--1.83, 0.6130.53, 0.10--2.84, 0.442[^7][^8]Table 4Stratification by diabetes in the association between low-testosterone and KS in men (≥20 years), NHANES 2011--2012.Table 4Total testosterone concentrationComorbidityYesNo≥3 ng/mL (ref)OR, 95% CI, *p*-valueOR, 95% CI, *p*-valueLow-testosteroneDiabetes0.62, 0.18--2.10, 0.4250.61, 0.42--0.90, 0.017[⁎](#tf0020){ref-type="table-fn"}[^9][^10]Table 5Stratification by lipid type and cut-off values in the association between Low-testosterone and KS in men (≥20 years), NHANES 2011--2012.Table 5Total testosterone concentrationLipid type and cut-off valueYesNo≥3 ng/mL (ref)OR, 95% CI, *p*-valueOR, 95% CI, *p*-valueLow-testosteroneHDL \> 40 mg/dL0.60, 0.40--0.90, 0.018[⁎](#tf0025){ref-type="table-fn"}0.62, 0.27--1.43, 0.251LDL \> 120 mg/dL1.51, 0.50--4.55, 0.4330.80, 0.31--2.06, 0.637TG \> 150 mg/dL0.17, 0.02--1.05, 0.0560.98, 0.41--2.33, 0.979Total Chol \>200 mg/dL0.71, 0.33--1.54, 0.3750.65, 0.34--1.26, 0.195Total Chol \>240 mg/dL12.54, 0.38--414.04, 0.1450.66, 0.43--1.01, 0.058[^11][^12]

When stratified by race/ethnicity, white men with low-testosterone had 48% lower odds of KS (OR: 0.52, 95% CI: 0.30--0.89) ([Table 6](#t0030){ref-type="table"}). Hispanic men with low-testosterone had 2.36 times higher odds of KS (OR: 2.36, 95% CI: 1.03--5.38), and there was no significant association in Black (non-Hispanic) men ([Table 6](#t0030){ref-type="table"}). There was no other significant association when stratified by other comorbidities and prescription drug use, (Supplementary tables).Table 6Stratification by race/ethnicity in the association between Low-testosterone and KS in Men (≥20 years), NHANES 2011--2012.Table 6Race/ethnicityWhiteBlackHispanicTestosteroneOR, 95% CI, *p*-valueOR, 95% CI, *p*-valueOR, 95% CI, *p*-value≥3 ng/mL (ref)1.00, N/A, N/A1.00, N/A, N/A1.00, N/A, N/A\<3 ng/mL0.52, 0.30--0.89, 0.021[⁎](#tf0030){ref-type="table-fn"}0.59, 0.24--1.45, 0.2372.36, 1.03--5.38, 0.042[⁎](#tf0030){ref-type="table-fn"}[^13][^14]

Age was a statistically significant factor in the association between testosterone and KS (Supplementary tables). When stratified by age, men in the age group ≥40--\<60 years and with low-testosterone had 68% lower odds of KS (OR: 0.32, 95% CI: 0.16--0.67, [Table 7](#t0035){ref-type="table"}) but this association was not statistically significant in other age groups, i.e., ≥20--\<40, ≥60--\<80, and ≥80 years.Table 7Stratification by age in the association between low-testosterone and KS in men (≥20 years), NHANES 2011--2012.Table 7Age groups≥20--\<40 years≥40--\<60 years≥60--\<80 years≥80 yearsTestosteroneOR, 95% CI, *p*-valueOR, 95% CI, *p*-valueOR, 95% CI, *p*-valueOR, 95% CI, *p*-value≥3 ng/mL (reference)1.00, N/A, N/A1.00, N/A, N/A1.00, N/A, N/A1.00, N/A, N/A\<3 ng/mL1.29, 0.45--3.64, 0.6060.32, 0.16--0.67, 0.004[⁎](#tf0035){ref-type="table-fn"}1.44, 0.43--4.80, 0.5262.44, 0.13--44.72, 0.524[^15][^16]

4. Discussion {#s0035}
=============

We found that men who were 20 years and older and with Low-testosterone had 41% lower odds of KS as compared to men without low-testosterone. Contrary to our finding, Otunctemur et al. ([@bb0110]) found that that men with testosterone concentrations \<2.85 ng/mL had three time higher odds of KS (OR: 2.93, 95%CI: 1.88--4.56). This could be due to insufficient adjustment for confounders, small sample size, and Berksonian bias in Otunctemur et al.\'s study ([@bb0110]). Furthermore, our finding was consistent with earlier studies. For example, higher testosterone levels were found in KS patients (3.30 ng/mL, SE: 2.50) as compared to controls (2.41 ng/mL, SE: 1.06; *p* = 0.003) ([@bb0085]). There was a significant and positive Pearson correlation between free serum testosterone levels and urinary oxalate concentrations (*R* = 0.297, *p*-value = 0.040) ([@bb0090]). Serum testosterone levels were significantly associated with higher urinary excretion of uric acid in patients with KS versus those without ([@bb0145]). Furthermore, kidney stones were consistently reported more often in men than women, and men biologically carry higher testosterone levels than women ([@bb0130]; [@bb0155]). The association between testosterone and KS in men could be explained by the upregulation of calcium oxalate biosynthesis by androgen receptors ([@bb0065]; [@bb0070]), and testosterone could have a biologic role in KS formation ([@bb0085]).

We found that the association between low-testosterone and KS differed by race/ethnicity. Our findings were consistent with the recent findings. For example, [@bb0180] demonstrated significant variation in total testosterone levels among race/ethnicity. Non-Hispanic Black and Hispanic were 63% and 40% less likely to have KS as compared to Non-Hispanic White, respectively ([@bb0130]).

We found that men who were obese (BMI ≥ 30 kg/m^2^) had 59% lower odds of KS when with low-testosterone ([Table 3](#t0015){ref-type="table"}). Obesity was strongly associated with KS ([@bb0010]; [@bb0050]; [@bb0165]), and low testosterone ([@bb0160]; [@bb0185]). Our finding suggests low-testosterone could prevent KS in obese men despite increased urinary excretion of calcium, oxalate, and uric acid ([@bb0165]).

We found men with low-testosterone and with HDL ≥ 40 mg/dL had 40% lower odds of KS. Our finding is consistent with prior literature. Men with HDL \< 45 mg/dL were 30% more likely to develop KS than men with HDL ≥45 mg/dL (HR: 1.30, 95% CI: 1.1--1.7) ([@bb0080]). Furthermore, patients with dyslipidemia were 20% more likely to develop KS as compared to patients without dyslipidemia (HR: 1.20, 95% CI: 1.01--1.51).([@bb0080]).

Despite the strengths of our study (e.g.; NHANES is a validated representative sample of the civilian noninstitutionalized U.S. male population, and there is oversampling of minorities and the elderly), our findings should be evaluated with caution because NHANES is a cross-sectional study; therefore, causality cannot be inferred in any of the observed associations or suggest any clinical practice change. There could be an inherent bias in the use of surveys, and measurements were largely obtained at a single-time point.

In conclusion, we found men with low-testosterone had significantly 41% lower odds of KS. This finding should be further studied in cohort studies that control for confounding and bias and with longitudinal follow-up of patients.
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Supplementary tablesImage 1

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.pmedr.2018.04.002>.

[^1]: Chi-square test is used for categorical variables, and t-test is used for continuous variables.

[^2]: KS: Kidney Stones, Low-testosterone: total testosterone concentrations \<3 ng/mL, ACE: Angiotensin Converting Enzyme, ARB: Angiotensin Receptor Blocker. Multivariable adjusted. OR: Odds ratio, 95% CI: 95 Percent Confidence Intervals, NE: Not Estimable; ng/mL: nanograms per milliliter. Type I Error: *p*-value threshold set at 0.05; α \< 0.05.

[^3]: Denotes statistical significance at *p* \< 0.05.

[^4]: KS: Kidney Stones Low-testosterone: total testosterone concentrations \<3 ng/mL. Multivariable adjusted. OR: Odds ratio, 95% CI: 95% Confidence Intervals. N/A: Not applicable. Type I Error: *p*-value threshold set at 0.05; α \< 0.05, (ng/mL: nanograms per milliliter)

[^5]: Adjusted for: age, education, marital status, race/ethnicity, overall obesity, alcohol use, physical activity, diabetes, heart attack, stroke, congestive heart failure, coronary heart disease, angina pectoris, hypertension, asthma, bladder cancer, gout, thyroid disease, prescribed drug use (a separate dichotomous variable for each drug use:7567 statin, angiotensin-renin blocker, ACE inhibitor, beta blocker, calcium channel, thiazide diuretic, loop diuretic, protease inhibitor, sulfonamide, aminopenicillin), total plain water drank yesterday (g), dietary calcium (mg), dietary sodium (mg), dietary protein (g), dietary fat (g), dietary vitamin D (mcg), dietary caffeine (mg), serum B12 (pg/mL), serum HDL-D cholesterol (mg/dL), low salt/low sodium diet (y/n), doctor\'s orders to lose weight (y/n), diet to reduce fat (y/n), diet to reduce salt (y/n), increasing exercise (y/n).

[^6]: Denotes statistical significance at *p* \< 0.05.

[^7]: KS: Kidney Stones Low-testosterone: total testosterone concentrations \<3 ng/mL. Multivariable adjusted. OR: Odds ratio, 95% CI: 95% Confidence Intervals. N/A: Not applicable. Type I Error: *p*-value threshold set at 0.05; α \< 0.05 (ng/mL: nanograms per milliliter), Adjusted for the same confounders as in model presented in [Table 2](#t0010){ref-type="table"}.

[^8]: Denotes statistical significance at *p* \< 0.05.

[^9]: KS: Kidney Stones Low-testosterone: total testosterone concentrations \<3 ng/mL. Multivariable adjusted. OR: Odds ratio, 95% CI: 95% Confidence Intervals. N/A: Not applicable. Type I Error: *p*-value threshold set at 0.05; [⁎](#tf0020){ref-type="table-fn"}α \< 0.05, (ng/mL: nanograms per milliliter), Men (≥20 years), Adjusted for the same number of confounders as in model presented in [Table 2](#t0010){ref-type="table"}.

[^10]: Denotes statistical significance at *p* \< 0.05.

[^11]: KS: Kidney Stones, Low-testosterone: total testosterone concentrations \<3 ng/mL, HDL: High Density Lipoprotein, LDL: Low Density Lipoprotein, TG: Triglycerides, Total Chol: Total Cholesterol. Multivariable adjusted. OR: Odds ratio, 95% CI: 95% Confidence Intervals. N/A: Not applicable. Type I Error: *p*-value threshold set at 0.05; α \< 0.05 (ng/mL: nanograms per milliliter; mg/dL: milligram per deciliter) Adjusted for the same number of confounders as in model presented in [Table 2](#t0010){ref-type="table"}.

[^12]: Denotes statistical significance at *p* \< 0.05.

[^13]: KS: Kidney Stones Low-testosterone: total testosterone concentrations \<3 ng/mL. Multivariable adjusted. OR: Odds ratio, 95% CI: 95% Confidence Intervals. N/A: Not applicable. Type I Error: *p*-value threshold set at 0.05; α \< 0.05 (ng/mL: nanograms per milliliter), Men (≥20 years) Adjusted for the same number of confounders as in model presented in [Table 2](#t0010){ref-type="table"}.

[^14]: Denotes statistical significance at *p* \< 0.05.

[^15]: KS: Kidney Stones Low-testosterone: total testosterone concentrations \<3 ng/mL. Multivariable adjusted. OR: Odds ratio, 95% CI: 95% Confidence Intervals. Type I Error: *p*-value threshold set at 0.05; [⁎](#tf0035){ref-type="table-fn"}α \< 0.05 (ng/mL: nanograms per milliliter), Men (≥20 years) Adjusted for the same number of confounders as in model presented in [Table 2](#t0010){ref-type="table"}.

[^16]: Denotes statistical significance at *p* \< 0.05.
